Abstract
Multiple myeloma represents 1% of all cancers and 15% of hematologic malignancies ([1][1]). Despite improvements in outcomes for this disease over the past several decades, the 5-year survival rate is still only 50%. Kidney dysfunction is common in myeloma, and it is present in 40% of patients at
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical journal of the American Society of Nephrology : CJASN
Paper Title
Journal
Date
